Intervention Protocol

Pegylated interferon for chronic hepatitis B

  1. Khalid Mumtaz1,*,
  2. Saeed Hamid2,
  3. Wasim Jafri3

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 24 JAN 2007

DOI: 10.1002/14651858.CD006303


How to Cite

Mumtaz K, Hamid S, Jafri W. Pegylated interferon for chronic hepatitis B (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD006303. DOI: 10.1002/14651858.CD006303.

Author Information

  1. 1

    Aga Khan University Hospital, Department of Medicine, Karachi, Pakistan

  2. 2

    Aga Khan University Hospital, Dept. of Medicine, Karachi, Sind, Pakistan

  3. 3

    The Aga Khan University Hospital, Medicine, Karachi, Sind, Pakistan

*Khalid Mumtaz, Department of Medicine, Aga Khan University Hospital, Stadium Road, P.O. Box 74800, Karachi, Pakistan. khalid.mumtaz@aku.edu. drkmumtaz@yahoo.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JAN 2007

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the beneficial and harmful effects of pegylated interferon alpha-2a (40 kilodalton (kd)) or pegylated interferon alpha-2b (12 kd) alone or in combination with other drugs, as compared with no treatment, placebo, or other antiviral drugs (except adefovir dipivoxil) for chronic hepatitis B, with HBeAg-positive or HBeAg-negative status.